Worth Venture Partners’s VistaGen Therapeutics VTGN Stock Holding History

Worth Venture Partners’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-5,278	Closed	-$203K	–	112
2019 Q1	$203K	Buy	+5,278	New	+$230K	0.11%	66

Other funds holding VTGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return

Worth Venture Partners's VTGN Position: Q2 2019 in Review

Worth Venture Partners sold out of VistaGen Therapeutics (VTGN) in Q2 2019, closing a stake of 5,278 shares — an estimated $203K sold.

Worth Venture Partners first reported a position in VTGN in Q1 2019 and held it in 1 quarter. The position peaked at $203K in Q1 2019. 21 funds tracked by Wall St. Rank hold VTGN as of Q2 2019.

Worth Venture Partners reported no remaining VistaGen Therapeutics position as of Q2 2019 after selling out during the quarter.
Worth Venture Partners sold 5,278 VistaGen Therapeutics shares in Q2 2019, an estimated $203K.
Worth Venture Partners first reported a position in VistaGen Therapeutics in Q1 2019 and held it in 1 quarter.
Worth Venture Partners's VistaGen Therapeutics position peaked at $203K in Q1 2019.
21 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2019.

Based on Worth Venture Partners's 13F filing for Q2 2019, filed 14 Aug 2019.